CEACAM5 and neoplasm: Crucially, the COLLISION trial stratified and balanced patients across established prognostic factors, including tumor size, number of metastases, baseline carcinoembryonic antigen (CEA), synchronous versus metachronous presentation, nodal status of the primary tumor, and receipt of neoadjuvant chemotherapy.